NORTH AUGUSTA, S.C.--(BUSINESS WIRE)--AmbioPharm, a worldwide leader in peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) services, announced the appointment of industry veteran Brian Gregg as Chief Executive Officer, today. Mr. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after 7 years with the company..

NORTH AUGUSTA，S.C.-（BUSINESS WIRE）-全球肽活性药物成分（API）合同开发和制造组织（CDMO）服务领导者AmbioPharm宣布任命行业退伍军人Brian Gregg担任首席执行官。Gregg先生在肽类CDMO行业拥有超过30年的经验，成功完成了Tim Nieters，他将在公司工作7年后辞职。。

Mr. Gregg joins AmbioPharm following a 32-year career at Bachem Americas, where he was Chief Operating Officer for nearly a decade and was responsible for driving business and operational growth with the strategic acquisition and integration of a competing peptide CDMO. During his earlier years at Bachem, Mr.

Gregg先生在Bachem Americas工作32年后加入AmbioPharm，在那里他担任首席运营官近十年，负责通过战略收购和整合竞争性肽CDMO推动业务和运营增长。在他早年在Bachem，先生。

Gregg led the quality and regulatory function for Bachem Americas before serving as site manager for Bachem’s GMP manufacturing location in Torrance, California. Mr. Gregg will play a pivotal role in expanding AmbioPharm’s leadership role in the fast-growing peptide CDMO market and growing the company’s global customer base..

Gregg在担任加利福尼亚州托伦斯Bachem GMP生产基地的现场经理之前，领导了Bachem Americas的质量和监管职能。Gregg先生将在扩大AmbioPharm在快速增长的肽类CDMO市场和增长公司全球客户群中的领导作用方面发挥关键作用。。

Dr. Juncai (Chris) Bai, Chairman of the Company, said, “We are excited to welcome Brian to our executive team. He has both the leadership experience and necessary background to be immediately effective in growing our business in the U.S. and globally, and we look forward to working with him as we continue to expand on our service offerings and global customer base.”.

公司主席Juncai博士（Chris）Bai说：“我们很高兴欢迎Brian来到我们的执行团队。他拥有领导经验和必要的背景，能够立即有效地在美国和全球范围内发展我们的业务，随着我们继续扩大服务产品和全球客户群，我们期待与他合作“。

Ms. Ling Yang, Managing Director of Carlyle and member of the Board, commented, “The industry sector continues to demonstrate significant growth, driven by end-market innovation globally, and we believe Brian has a demonstrated and proven industry track record to lead AmbioPharm in its next phase of growth.

Carlyle总经理兼董事会成员Ling Yang女士评论说：“在全球最终市场创新的推动下，行业继续显示出显着的增长，我们相信Brian已经证明并证明了行业领先的行业记录AmbioPharm处于下一个增长阶段。

Carlyle has worked with AmbioPharm since our investment in 2018 to help transform the company and build out its operational capabilities, and we continue to provide unwavering support to the company as it seeks to expand its leading position in the CDMO market.”.

自2018年投资以来，Carlyle一直与AmbioPharm合作，帮助转型公司并建立运营能力，我们继续为公司提供坚定的支持，因为公司试图扩大其在CDMO市场的领先地位“。

Mr. Gregg said, “AmbioPharm has invested significant effort and capital building out its systems, organization, buildings, and equipment, and the company is well-positioned to capture the opportunities in the global peptide CDMO market. It is an exciting time to take the reins of the company and I look forward to working with the leadership team to capitalize on these opportunities as well as to deliver high-quality products and service excellence for AmbioPharm’s customers.”.

格雷格先生说， “AmbioPharm在其系统，组织，建筑和设备方面投入了大量精力和资金建设，公司处于有利地位，能够抓住全球肽类CDMO市场的机会。现在是一个激动人心的时刻，重新建立公司和我期待与领导团队合作，利用这些机会并提供高qAmbioPharm客户的优质产品和卓越服务“。

Mr. Gregg holds an MBA from the San Diego State University and a Bachelor of Arts degree in Chemistry from the University of California at San Diego.

Gregg先生持有圣地亚哥州立大学的工商管理硕士学位，加州大学圣地亚哥分校的化学艺术学士学位。

About AmbioPharm

关于AmbioPharm

AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA, specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at small to very large scales. Its manufacturing facilities in South Carolina, USA and Shanghai, China, manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide.

AmbioPharm是一家全球多肽CDMO，成立于2005年，总部设在美国南卡罗来纳州的北奥古斯塔，致力于开发小到非常大规模的基于肽的活性药物成分（API）的高效制造工艺。其在美国南卡罗来纳州和中国上海的制造工厂为全球客户制造cGMP下的新化学实体（NCE）和通用肽API。

The company currently has over 600 employees in North America, Asia and Europe..

该公司目前在北美，亚洲和欧洲拥有600多名员工。。